Background: Airway hyperresponsiveness is a major feature of asthma attributed predominantly to an extrinsic immune/ inflammatory response increasing airway smooth muscle (ASM) contractility. Objective: We investigated whether increased ASM expression of orosomucoid-like 3 (ORMDL3), a gene on chromosome 17q21 highly linked to asthma, induced increased ASM proliferation and contractility in vitro and influenced airway contractility and calcium flux in ASM in precision-cut lung slices (PCLSs) from wild-type and hORMDL3
Airway hyperresponsiveness (AHR) is a major feature of asthma. 1 Conceptually, AHR can be due to either an intrinsic abnormality in airway smooth muscle (ASM) resulting in increased contractility or to an extrinsic effect of inflammatory cells and their mediators on ASM to increase contractility. The effects of extrinsic airway inflammation on ASM are considered the primary driving force for increased AHR mediated by ASM in asthmatic patients. Thus the presence of airway inflammation in asthmatic patients forms the basis for National Institutes of Health expert panel recommendations regarding early institution of anti-inflammatory therapy to reduce persistent asthma symptoms and exacerbations and improve lung function and AHR. 1 Episodes of airway inflammation in asthmatic patients are commonly triggered by either viruses or allergen and are associated with release of inflammatory mediators from a variety of lung-resident (mast cell, epithelium, and macrophage) and recruited cells (eosinophils, T cells, and neutrophils) that can contribute to increased ASM contractility, AHR, and airway remodeling and decreased lung function. 1 In contrast to this well-established role of extrinsic inflammation contributing to increased ASM contractility and AHR, the role of an intrinsic abnormality in ASM contributing to increased ASM contractility and AHR are less well established. Theoretically, the contribution of an intrinsic abnormality in ASM to AHR might be mediated by either increased amounts of ASM, increased expression of contractile proteins in ASM cells, and/or increased activation of the contractile apparatus.
2-4 ASM contraction is initiated by calcium and calmodulin binding to activate myosin light chain (MLC) kinase, which phosphorylates MLC to form cross-bridge cycling of MLC with actin filaments. 4 Thus regulation of the intracellular Ca 21 ([Ca 21 ] i ) concentration in ASM is essential for airway contraction.
Mathematic models suggest that an increased amount of ASM in the airway submucosa is sufficient to cause AHR through mechanical effects alone. [5] [6] [7] The presence of increased ASM mass in the large and small airways in asthmatic patients is well described 3, [8] [9] [10] [11] [12] [13] and considered a major contributor to bronchoconstriction of the airways and persistent airflow obstruction. 6, 11 The increase in ASM in asthmatic patients can be due to hyperplasia, 3 hypertrophy, 11 or both. There are studies demonstrating ASM hypertrophy in patients with severe asthma 10, 11 but not in those with mild asthma. 3 There are several studies demonstrating that ex vivo asthmatic ASM proliferation (ie, hyperplasia) is increased compared with that in nonasthmatic subjects. 12, 13 Studies of ASM obtained by means of laser capture from patients with mild asthma and control subjects have shown that ASM cell numbers were nearly 2-fold higher in asthmatic patients, and the amount of ASM in the submucosa was increased 50% to 83%. 3 As with studies of ASM hypertrophy in asthmatic patients, there are some studies that have not demonstrated increased proliferation of asthmatic ASM ex vivo.
14 Thus, although there is extensive evidence from multiple laboratories that there is increased ASM in asthmatic patients, 3, [8] [9] [10] [11] [12] [13] the mechanism mediating the increased ASM is understood incompletely. Current paradigms consider ASM as a target of mediators released from inflammatory cells in the airway that result in ASM changes (hypertrophy and hyperplasia) and increased AHR. Thus the mechanisms behind these changes in ASM are considered to be mediated by repeated episodes of airway inflammation in asthmatic patients rather than an intrinsic abnormality in ASM. 1 Our previous studies of orosomucoid-like 3 (ORMDL3), a gene on chromosome 17q21 that is highly linked to asthma in genome-wide association studies, 15 demonstrated that mice generated to express universal increased levels of human ORMDL3 (hORMDL3 Zp3-Cre mice) had spontaneously increased ASM and increased AHR in the absence of airway inflammation. 16 These results suggest that ORMDL3 might be a key gene regulating ASM hypertrophy and hyperplasia and, more importantly, that lung structural cells (eg, ASM), rather than inflammatory cells, expressing increased ORMDL3 might be the cells contributing to the increased AHR, as observed in hORMDL3
Zp3-Cre mice. In this study we make the novel observation that ORMDL3 upregulates the cardinal features of asthma, including ASM proliferation, contractility, and Ca 21 oscillations in ASM cells. We also provide evidence that ORMDL3 (localized to the endoplasmic reticulum) 17 upregulates sarcoendoplasmic reticulum calcium ATPase (SERCA) 2b (localized in proximity to ORMDL3 in the sarcoplasmic endoplasmic reticulum), 18 which regulates Ca 21 flux and contractility in ASM cells. Therefore this ORMDL3, SERCA2b, Ca 21 oscillation, and ASM contractility pathway in ASM might be an important genetic pathway intrinsic to ASM, leading to increased AHR in the 62% of asthmatic patients harboring the single nucleotide polymorphism (SNP) on chromosome 17q21 linked to increased levels of ORMDL3 expression. 15 These studies support the paradigm that ASM changes and AHR in asthmatic patients not only are driven by extrinsic inflammation but also can be mediated by an intrinsic abnormality in lung structural cells, such as ASM.
METHODS

Generation of hORMDL3
zp3-Cre chimeric mice hORMDL3 zp3-Cre chimeric mice were generated as described in the Methods section in this article's Online Repository at www.jacionline.org. 16 
ASM studies in vitro
The methods for mouse airway smooth muscle (mASM) or human airway smooth muscle (hASM) culture, transfection with ORMDL3 or SERCA2b, small interfering RNA (siRNA) knockdown with SERCA2b, quantitation of ASM proliferation and contraction in vitro, and quantitative RT-PCR (RT-qPCR) are described in the Methods section in this article's Online Repository. 16, 19 Mouse precision-cut lung slices
Methods for generation of precision-cut lung slices (PCLSs), measurement of mouse airway contraction and relaxation, and measurement of Ca 21 signaling are described in the Methods section in this article's Online Repository.
20-23
Statistical analysis
All data are reported as means 6 SEMs. A P value of less than .05 was considered significant. Detailed methods for statistical analysis are described in the Methods section in this article's Online Repository.
RESULTS
Chimeric hORMDL3
Zp3-Cre mice have increased ASM without airway inflammation Because our previous studies demonstrated that naive hORMDL3
Zp3-Cre mice have increased ASM without airway inflammation, 16 we generated bone marrow chimeric mice in which the hORMDL3
Zp3-Cre chimeric mouse had wild-type (WT) bone marrow (with no expression of hORMDL3), and mouse lung structural cells expressed increased levels of hORMDL3. Establishment of chimerism (WT bone marrow into an irradiated hORMDL3
Zp3-Cre recipient) was confirmed by using RT-qPCR, demonstrating hORMDL3 expressed in the lungs but not the blood or bone marrow leukocytes of hORMDL3
Zp3-Cre chimeric mice (Fig 1, A) . These studies demonstrated that 12-week-old naive chimeric hORMDL3
Zp3-Cre mice had increased levels of peribronchial smooth muscle (P < .05 vs the WT control), as assessed by means of image analysis quantitation of the area of a-smooth muscle actin immunostaining (Fig 1, B-E) . The naive chimeric hORMDL3
Zp3-Cre mice with increased ASM did not have evidence of airway inflammation (Fig 1, F) . These studies provide evidence that lung structural cell expression of hORMDL3 is sufficient to induce increased ASM independent of airway inflammation.
However, these bone marrow chimera studies are unable to identify which lung structural cell expressing ORMDL3 (ASM, fibroblast, and epithelium) is able to induce increased ASM mass independent of airway inflammation.
hASM cells expressing increased levels of ORMDL3 have increased proliferation, contraction, and expression of SERCA2b
To determine whether ASM expression of ORMDL3 itself could contribute to the increased ASM observed in naive chimeric hORMDL3
Zp3-Cre mice, we transfected normal hASM cells with hORMDL3 (Fig 2, A and B) . These studies demonstrated that Ad-ORMDL3-green fluorescent protein (GFP)-transfected hASM cells had significantly increased proliferation, as assessed based on Ki67 mRNA (Fig 2, C) and hASM cell counts (Fig 2, D) , compared with an empty vector control. In addition, Ad-ORMDL3-GFP-transfected hASM cells had significantly increased contractility in response to acetylcholine (Fig 2,  E and F ). These studies demonstrate that increased ORMDL3 in hASM can induce increased proliferation, and increased hASM contractility which is a major feature of asthma. zp3-Cre chimeric mice and increased ASM. WT and hORMDL3 zp3-Cre mice (n 5 8 mice per group) were irradiated, and each was injected intravenously with WT bone marrow and killed 12 weeks later. A, Efficiency of chimerism was assessed by using RT-qPCR to detect expression of human ORMDL3 in blood and lungs. BM, Bone marrow. B-E, Lungs of chimeric mice (n 5 8 mice per group) were immunostained with an anti-a-smooth muscle actin antibody, and the area of peribronchial anti-a-smooth muscle actin immunostaining was quantitated by using image analysis. F, Lungs of chimeric mice (n 5 8 mice per group) were immunostained with either an anti-CD4, anti-F4/80, anti-MBP, or anti-neutrophil elastase antibody, and the number of peribronchial cells with positive immunostaining was quantitated by using image analysis.
FIG 2. ORMDL3, SERCA2b
, and ASM proliferation and contraction. Primary hASM cells were transfected with Ad-ORMDL3-GFP or, as a control, the empty vector Ad-GFP. A and B, Efficiency of transfection was assessed by using immunofluorescence microscopy (Fig 2, A) and fluorescence-activated cell sorting (Fig  2, B) . C and D, hASM cell proliferation was assessed 72 hours later either by means of RT-qPCR of Ki67 mRNA levels (n 5 3 per group; Fig 2, C) or based on ASM cell counts using light microscopy (n 5 6 per group; Fig 2, D) . E and F, hASM cell contraction (n 5 3 per group) was assessed in a gel contraction assay in hASM cells transfected with either Ad-ORMDL3-GFP or Ad-GFP in the presence or absence of acetylcholine (Ach). Ad-ORMDL3 vs Control: P < .05; Ad-ORMDL3 versus Ad-ORMDL31Ach: P < .05; Ad-ORMDL31Ach versus Control1Ach: P < .05; Ad-ORMDL3 versus Control1Ach: P 5 .20; Control versus Control1Ach: P < .05. G, Levels of SERCA2b (n 5 3 per group) were quantitated by using RT-qPCR in hASM cells transfected with either Ad-ORMDL3-GFP or Ad-GFP. H, Levels of hASM proliferation (n 5 3 per group) were assessed by using RT-qPCR of Ki67 mRNA levels in hASM cells transfected with either Ad-SERCA2b or control. I and J, hASM contraction (n 5 3 per group) was assessed in a gel contraction assay in hASM cells transfected with either Ad-SERCA2b or Ad empty vector control in the presence or absence of Ach. Ad-SERCA2b versus control: P < .05; Ad-SERCA2b versus Ad-SERCA2b1Ach: P 5 .13; Ad-SERCA2b31Ach vs Control1Ach: P < .05; Ad-SERCA2b versus Control1Ach: P < .05. zp3-Cre (red line) mice, respectively, to an increased dose of MCh (Fig 3, B) and 5-HT (Fig 3, C) at 378C, followed by comparison of the dose-response curve to MCh (Fig 3,D) and 5-HT (Fig 3, E) between WT (blue line) and hORMDL3 zp3-Cre (red line) mice. hORMDL3 zp3-Cre vs WT: *P < .05. Each line in Fig 3, B and C, represents the mean, and each point represents the mean 6 SEM at selected time points of the airway lumen area normalized to the initial size at a time of 0 seconds. Previously, we demonstrated that hORMDL3 Zp3-Cre mice have increased expression of the calcium pump SERCA2b in their lungs 16 but have not previously investigated whether ORMDL3 regulates SERCA2b in ASM and whether this influences ASM contractility. Thus we transfected Ad-ORMDL3-GFP into hASM cells, which resulted in significantly increased levels of expression of SERCA2b in hASM cells (Fig 2, G) . The importance of SERCA2b induction by ORMDL3 is suggested from subsequent studies in which we transfected normal hASM cells with Ad-SERCA2b. These studies demonstrated that Ad-SERCA2b-transfected hASM cells had significantly increased proliferation as assessed by Ki67 mRNA (Fig 2, H) compared with empty vector control. In addition, Ad-SERCA2b-transfected hASM had significantly increased contractility compared with control-transfected hASM (P <.05; Fig 2, I and J), which is consistent with in vivo studies demonstrating increased cardiac smooth muscle contractility in mice expressing increased levels of SERCA2b in the heart. 24, 25 Incubation of Ad-SERCA2b-transfected hASM cells with acetylcholine in vitro resulted in a trend for increased ASM contractility, which was not statistically significant (Ad-SERCA2b vs Ad-SERCA2b plus acetylcholine, P 5 .13; Fig 2, J) . Thus the majority of the increased ASM contractility in Ad-SERCA2b-transfected ASM incubated with acetylcholine was due to Ad-SERCA2b transfection rather than acetylcholine. These studies demonstrate that in hASM cells increased SERCA2b (a downstream pathway from ORMDL3) 16, 17 can induce increased proliferation and increased hASM contractility, providing evidence for an intrinsic pathway in hASM in which ORMDL3 upregulates SERCA2b, resulting in increased hASM and increased contractility.
Increased airway contraction in hORMDL3
Zp3-Cre mouse PCLSs
To determine whether ORMDL3 expression in the lung influences airway contraction, we visualized (Fig 3, A , and see Video E1 in this article's Online Repository at www.jacionline. org) and quantitated (Fig 3, B-E) airway contractility in naive hORMDL3
Zp3-Cre mouse PCLSs, which reflects the in situ physiology of mASM of relatively smaller airways devoid of a blood supply and thus unable to recruit inflammatory or immune cells from the circulation. To quantitate airway contraction in PCLSs, we used both methacholine (MCh; a cholinergic agonist used to assess AHR in asthma) and 5-hydroxytryptamine (5-HT), which each trigger Ca 21 4, 27, 28 There was no significant difference in the baseline size of airways chosen for testing between hORMDL3 zp3-Cre mice and the WT group (see Fig E1, A-D, in this article's Online Repository at www.jacionline.org). In addition, no precontraction of the airways was observed in either hORMDL3 zp3-Cre or WT mice because none of the airways showed relaxation to (R,R)-formoterol, a long-acting b 2 -receptor agonist that relaxes ASM by inactivating MLC kinase and activating MLC phosphatase (see Fig E1, E and F). Both MCh (Fig 3, B) and 5-HT (Fig 3, C) induced a dose-dependent increase in airway contraction in WT mouse PCLSs at 378C. Compared with WT mice, the extent of airway contraction in hORMDL3 zp3-Cre mice was significantly increased for both MCh (Fig 3, B and D, and see Video E1) and 5-HT (Fig 3, C and E) at all concentrations tested (100 to 2000 nmol/L), suggesting an overall increased airway contractility in hORMDL3 zp3-Cre mice. A similar pattern of increased airway contraction in hORMDL3 zp3-Cre mice was noted at room temperature (see Fig E2 in this article's Online Repository at www.jacionline.org). These studies demonstrate that increased ORMDL3 expression in naive lung PCLSs without a blood supply results in increased airway reactivity to agonists, including MCh, a major feature of asthma.
Increased Ca 21 oscillation frequency in ASM cells in hORMDL3
Because ORMDL3 induced increased ASM expression of SERCA2b (Fig 2, G) Fig 4, A-D , as a change in fluorescence intensity of Oregon Green (white color change in ASM cells in Fig 4, A-C, and normalized intensity change in Fig 4, D) recorded at baseline before MCh at 0 seconds (Fig 4, A) and at 2 time points after MCh: 1.07 seconds (Fig 4, B) and 1.97 seconds (Fig 4, C; scale bar 5 20 mm). E, Representative trace shows that 400 nmol/L MCh induced Ca 21 oscillations in an ASM cell at 378C, which was sustained until MCh was washed off by using sHBSS; adding back MCh would induce Ca 21 oscillations again. F-I, Representative traces show Ca 21 oscillations of ASM cells in PCLSs derived from WT (Fig 4, F) and hORMDL3 zp3-Cre (Fig 4, G) mice, respectively. The response to an increased dose of MCh at 378C, followed by a comparison of dose-response curve to MCh (Fig 4, H) and 5-HT (Fig 4, I ) between WT (blue line) and hORMDL3 zp3-Cre (red line) mice is shown. hORMDL3 zp3-Cre versus WT mice: *P < .05. Representative traces are expressed as intensity (F t ) normalized to the initial intensity at time of 0 seconds (F 0 ) measured from a region of interest with a size of 8 3 10 pixels within a single ASMC. Data in waves propagating along the length of the mASM cells (Fig 4, A-E, and see Video E2 in this article's Online Repository at www.jacionline.org). These Ca 21 oscillations were accompanied by contraction and shortening in mASM cells, resulting in airway contraction (Fig 3, A) . In the mASM cell in PCLSs of WT mice (Fig 4, F) , MCh induced a concentration-dependent increase in Ca 21 oscillation frequency in a similar way as observed in airway contraction. Compared with WT mice, the Ca 21 oscillation frequency in mASM cells in PCLSs of hORMDL3 zp3-Cre mice were significantly increased for both MCh (Fig 4, G and H) and 5-HT (Fig 4, I) zp3-Cre mice were increased compared with those in WT mice (Fig 5, A) , as quantitated by using RT-qPCR. In hASM cells we detected SERCA2b but not SERCA2a (Fig 5, B) . We then used siRNA to knock down SERCA2b expression in hASM cells. siRNA knockdown of SERCA2b was efficient in hASM cells (Fig 5, C) . siRNA knockdown of SERCA2b significantly inhibited hASM contraction in vitro in response to histamine starting within 15 minutes of exposure to histamine (Fig 5, D) . Control scrambled siRNA did not inhibit histamine-induced hASM contraction. These results demonstrated an important role of SERCA2b in ASM contractility in vitro.
To further confirm the role of SERCA2b in airway contraction and underlying Ca 21 oscillations in ASM cells, we investigated the effect of cyclopiazonic acid (CPA), a specific SERCA pump inhibitor, 29 on MCh-induced airway contraction, as well as Ca 21 oscillations in ASM cells in mouse PCLSs (Fig 5, E-H , and see Fig E4 in this article's Online Repository at www.jacionline.org). Treatment of MCh-contracted airways with CPA (from 500 nmol/L to 5 mmol/L) relaxed airway contraction in a concentration-dependent manner (Fig 5, E and  F) , and 5 mmol/L CPA induced nearly 73% relaxation as normalized to the control (Fig 5, F) . Consistently, CPA also inhibited MCh-induced Ca 21 oscillations in a concentrationdependent manner (Fig 5, G and H) , whereas 5 mmol/L CPA gradually stopped Ca 21 oscillations in 15 minutes (Fig 5, G) .
DISCUSSION
This study makes the novel observation that ORMDL3 expression in ASM can explain the strong genetic linkage of ORMDL3 on chromosome 17q21 to asthma. 15 In addition, this study provides evidence that intrinsic expression of a gene highly linked to asthma in ASM can lead to increased ASM proliferation and contractility independent of extrinsic inflammation. Thus asthma might be a disease of both airway inflammation and an intrinsic change in ASM. In support of this, we demonstrate that ORMDL3 expression in ASM cells in vitro induces increased ASM proliferation and increased ASM contractility to acetylcholine. In addition, in vivo studies demonstrate that naive hORMDL3
Zp3-Cre chimeric mice with ORMDL3 expressed in lung structural cells (but not in bone marrow-derived inflammatory and immune cells) have increased ASM in the absence of lung inflammation. Importantly, in vivo studies demonstrate that ASM in naive hORMDL3
Zp3-Cre mouse PCLSs without a blood supply has increased contractility and increased Ca 21 oscillation frequency, a fundamental signaling mechanism mediating ASM contraction, in response to MCh and 5-HT.
Taken together, these studies underscore the important role that ORMDL3 expressed in ASM plays in inducing increased ASM proliferation and increased ASM contractility to MCh, a major feature of asthma. However, this study is unable to determine whether ORMDL3 induces increased AHR through effects on increasing ASM proliferation, increasing ASM contractility, or both. Because ORMDL3 is highly linked to childhood asthma in genetic epidemiology studies, 15 ORMDL3 expression in ASM might help explain why subjects with the SNP linked to A, RT-qPCR was used to detect levels of SERCA2b mRNA in mASM cells derived from either hORMDL3 zp3-Cre mice or WT control mice (n 5 6 per group). B, Levels of SERCA2a and SERCA2a and SERCA2b mRNA were quantitated by using RT-qPCR in hASM cells (n 5 6 per group). C, Levels of SERCA2b mRNA were quantitated in hASM cells in which SERCA2 siRNA was used to knockdown SERCA. Scrambled siRNA was used as a control (n 5 4 per group). D, hASM contraction was assessed in a gel contraction assay for 0 to 60 minutes in the presence of histamine in hASM cells in which siRNA (or scrambled control siRNA) was used to knock down SERCA2 (n 5 8 per group). SERCA2 siRNA vs scrambled siRNA: **P < .01. E and F, Effect of CPA (500-5000 nmol/L) on airways contracted with 400 nmol/L MCh in PCLSs derived from WT mice (Fig 5, E) , followed by a summary of relaxation effect normalized to control values (Fig 5, F) . Control mice were treated with vehicle of 0.5% dimethyl sulfoxide (DMSO) in HBSS supplemented with 20 mmol/L HEPES buffer (sHBSS; P < .01). Each line in Fig 5, E, represents the mean, and each point represents the mean 6 SEM at selected time points of the airway lumen area normalized to the initial size at time 0 seconds. Data in Fig 5, The concept that T H 2 inflammation is important to the development of allergic disease in the upper and lower airways is well accepted. However, there is limited insight into why certain subjects with the same level of T H 2 inflammation will have only allergic rhinitis (with no asthma), whereas others will have allergic rhinitis and asthma. In this study we provide evidence that ORMDL3, a gene linked most highly to asthma 15 (but not linked to allergic rhinitis 30 ), when expressed in lung structural ASM cells in vitro or in vivo spontaneously induced increased airway contractility to MCh without an additional inflammatory stimulus. This might help explain how T H 2 inflammation, when combined with an ASM-expressed asthma-associated gene, such as ORMDL3, can result in allergic rhinitis and asthma, whereas T H 2 inflammation alone in the absence of an abnormality in ASM might result in allergic rhinitis but not asthma. ORMDL3 has been linked to asthma 15 but not allergic rhinitis, 30 underscoring differences between asthma and allergic rhinitis. In addition, the SNP linked to increased ORMDL3 expression in asthmatic patients is common, affecting approximately 62% of children with asthma. 15 Another example of a structural gene being important to allergic disease is loss of function of the filaggrin gene in epithelial cells in the skin of patients with atopic dermatitis, which influences barrier function in T H 2 inflammation in the skin. 31 Previous studies have also provided evidence that AHR can be independent from airway inflammation. For example, a study of patients with allergic asthma did not find a correlation between AHR to MCh and levels of inflammatory cells in sputum, bronchoalveolar lavage fluid, or bronchial biopsy specimens. 32 In addition, inhaled corticosteroids can effectively reduce levels of airway inflammation but only attenuate AHR. 33 Patients with eosinophilic bronchitis can also have severe inflammation but no AHR. 34 Population studies have also demonstrated that AHR has an estimated heritability of 30% to 66%. 35, 36 Thus although airway inflammation plays an important role in the pathogenesis of asthma, there are likely genetic and airway components (airway inflammation and airway remodeling) that contribute to levels of AHR in asthmatic patients. 36 Our study also provides evidence that SERCA2b might be the downstream pathway by which ORMDL3 influences ASM contractility. Our prior studies have demonstrated that in human lung epithelial cells, increased expression of hORMDL3 activates several downstream pathways, including activating transcription factor 6a, SERCA2b, sphingolipids, chemokines, and remodeling pathways. 16, 17 Because ORMDL3 regulates several downstream pathways, some of these pathways might be more important in ASM compared with other cell types expressing ORMDL3. For example, the importance of increased SERCA2b to ASM hypertrophy and increased contractility is suggested from studies of the heart, in which mice expressing increased levels of SERCA2b in the heart had increased cardiac contractility and increased Ca 21 flux in cardiomyocytes and increased cardiac muscle hypertrophy. 24, 25 SERCAs are intracellular ATP-driven Ca 21 pumps that transport Ca 21 from the cytoplasm into the sarcoendoplasmic reticulum (the domain of the endoplasmic reticulum that lacks ribosomes). 18, 37 SERCA proteins are encoded by 3 genes Serca1, Serca2, and Serca3, of which SERCA2 is the only SERCA expressed in ASM. 18, 37 Alternative splicing of the Serca2 gene encodes 2 major protein isoforms: SERCA2a, which is expressed predominantly in cardiomyocytes and slow-twitch skeletal muscle, 18, 37 and SERCA2b, the focus of this study, which is expressed in ASM and most tissues. 18 38, 39 In this study we demonstrate that ORMDL3 increases levels of SERCA2b in ASM, which is associated with increased frequency of Ca 21 oscillations in ASM. In addition, increased levels of SERCA2b in ASM increases ASM proliferation, whereas siRNA knockdown of SERCA2b reduces ASM contractility. Furthermore, inhibition of SERCA by administering CPA in PCLSs reduced Ca 21 oscillation frequency in ASM cells and thus airway contraction in a dose-dependent manner. These results together suggest that SERCA2b, which is regulated by ORMDL3 in ASM, plays an important role in sustaining agonists-induced Ca 21 oscillations in ASM cells and is associated with increased airway contractility as shown in PCLSs of hORMDL3
Zp3-Cre mice. Transfection of SERCA2b into ASM resulted in greater enhancement of contraction than that noted with transfection of ORMDL3. One possible explanation for these results is that transfection of ORMDL3 not only increases SERCA2b expression (which increases ASM contractility) but also inhibits function of the enzyme serine palmitoyl transferase or SPT (which could reduce ASM contractility). 40 For example, increased levels of ORMDL3 inhibit the enzyme SPT, the first and rate-limiting step in sphingolipid synthesis, resulting in lower levels of sphingosine-1-phosphate (S1P). 40 Because S1P induces ASM contraction, 41 lower levels of S1P induced by increased levels of ORMDL3 could reduce ASM contractility. Thus ORMDL3 induction of SERCA2b could increase ASM contractility, whereas its concomitant induction of the enzyme SPT could reduce S1P and reduce ASM contractility. Thus the net effect of ORMDL3 on ASM contractility might be less than that of SERCA2b because of the induction not only of SERCA2b but also inhibition of S1P by ORMDL3. Interestingly, therapeutically targeting Ca 21 signaling pathways in smooth muscle in asthmatic patients to influence smooth muscle contractility and AHR is currently an active area of investigation. 42 However, there are also studies that question whether Ca 21 signals change in ASM from asthmatic patients while stimulated with agonists. 13, 43, 44 Interestingly, some studies have reported that decreased expression of SERCA in ASM from asthmatic patients contributes to airway remodeling. 43 It should be noted that our study differs from a prior study 43 in examining the effect of increased ORMDL3 expression (simulating asthmatic patients with the SNP on chromosome 17q21 linked to increased ORMDL3 expression) on SERCA2b in ASM, whereas the prior study did not genotype asthmatic patients to determine whether they had the SNP associated with increased ORMDL3 expression, which we demonstrated is associated with increased SERCA2b expression. Thus we hypothesize that based on genotype, not all asthmatic patients will have increased SERCA2b expression.
In addition, prior studies have demonstrated that suppressed SERCA expression by cytokines might slow the [Ca 21 ] i response to agonists and thus maintain a relatively high [Ca 21 ] i concentration, leading to increased ASM contractility. 45 In agreement with this, our results showed that treatment of PCLSs with a high dose (10 mmol/L) of CPA stopped MCh-induced Ca 21 oscillations and led to an increase in [Ca 21 ] i baseline in ASM cells with partially contracted airways (see Fig E4) . However, a lower dose of CPA (from 500-5000 nmol/L) reduced Ca 21 oscillations and airway contraction in a dose-dependent manner, suggesting that under a certain range, increased/decreased SERCA expression is proportional to increased/decreased Ca 21 oscillations and therefore increased/decreased airway contraction, whereas full block or knockdown of SERCA would result in an [Ca 21 ] i plateau that mediates only an impaired ASM contraction response to agonists.
46
ORMDL3 is expressed in multiple cell types, including lung structural cells (epithelium and smooth muscle) and immune and inflammatory cells (T cells, eosinophils, and macrophages). 16, 17 Because the SNP linking chromosome 17q21 to asthma is associated with increased ORMDL3 expression, 15 we have previously used cre-lox techniques to generate mice selectively deficient in ORMDL3 in airway epithelium (Ormdl3 D2-3/D2-3
CC10)
41 to simulate an inhaled therapy that effectively inhibited ORMDL3 expression in the airway. In contrast to the anticipated reduction in AHR, allergenchallenged Ormdl3 D2-3/D2-3 CC10 mice had a significant increase in AHR compared with WT mice.
41 S1P levels were significantly increased in Ormdl3 D2-3/D2-3 CC10 mice, as well as in airway epithelial cells in which ORMDL3 was inhibited with siRNA, and incubation of S1P with ASM cells significantly increased contractility. 41 Overall, Ormdl3
D2-3/D2-3 CC10 mice exhibit increased allergen-induced AHR independent of inflammation and associated with increased S1P generation. 41 These studies suggest that therapies that selectively and effectively inhibit ORMDL3 in the airway epithelium in asthmatic patients might not be the best cell to target. Further studies are needed to determine whether targeting reduction of ORMDL3 in airway ASM would reduce AHR.
In summary, in this study we provide evidence that an intrinsic gain of function in ORMDL3 in ASM can influence ASM contractility in asthmatic patients by demonstrating that increased ORMDL3 expression in ASM cells induces increased expression of SERCA2b with consequent increased Ca 21 oscillation in ASM cells and increased ASM contractility. Overall, these studies provide evidence that ORMDL3 (a gene on chromosome 17q21 highly linked to asthma in genome-wide association study) 15 can induce increased ASM contractility in the absence of inflammation. Because AHR can be driven conceptually by chronic inflammation inducing increased ASM contractility and/or an intrinsic change in ASM inducing increased ASM hyperplasia and contractility, this study provides evidence that targeting a gene inducing a fundamental abnormality in ASM, such as ORMDL3, might result in a new therapeutic approach to the treatment of asthma.
Key messages
d Increased ASM expression of ORMDL3 induces increased ASM proliferation and contractility in vitro.
d PCLSs derived from naive hORMDL3 Zp3-Cre mice (which express increased levels of human ORMDL3) that do not have airway inflammation exhibit increased airway contractility with increased calcium oscillations in ASM cells.
d In addition to extrinsic inflammation, intrinsic ASM expression of ORMDL3 can increase ASM contractility and proliferation and might contribute to increased AHR in asthmatic patients.
METHODS
Animal care and use
All the mouse experimental protocols described were approved by the University of California, San Diego (UCSD), and the University of Massachusetts Medical School Institutional Animal Care and Use Committees.
Generation of hORMDL3
zp3-Cre chimeric mice hORMDL3 zp3-Cre mice on a C57Bl/6 background, which universally express the human ORMDL3 gene, were genotyped to confirm expression of the human ORMDL3 gene and used in these studies as previously described in this laboratory. E1 Littermate controls are referred to as WT mice. Recipient mice (WT and hORMDL3 zp3-Cre mice) were irradiated once with 450 rad. Donor bone marrow from WT or hORMDL3 zp3-Cre mice was isolated from both tibias and fibulas, and approximately 10 million cells were injected 1 hour after irradiation to recipient mice through tail veins. Mice were rested for 30 days before sacrifice. Efficiency of chimerism was assessed by using RT-qPCR to detect human ORMDL3 expression in peripheral blood and lung tissue.
Lung processing
Lungs were processed for immunohistology (paraffin-embedded lung sections), as previously described in this laboratory.
E2
For paraffin-embedded sections, lungs were equivalently inflated with an intratracheal injection of the same volume of 4% paraformaldehyde solution (Sigma, St Louis, Mo) to preserve the pulmonary architecture.
Peribronchial smooth muscle layer
Thickness of the mASM layer was measured by using a-smooth muscle actin immunohistochemistry, as previously described. E3 Lung sections were immunostained with an anti-a-smooth muscle actin primary antibody (Sigma-Aldrich) to detect peribronchial smooth muscle. Species-and isotype-matched antibodies were used as controls in place of the primary antibody. The area of peribronchial a-smooth muscle actin staining in paraffin-embedded lungs was outlined and quantified under a light microscope (Leica DMLS; Leica Microsystems, Wetzlar, Germany) attached to an image analysis system (Image-Pro Plus; Media Cybernetics, Bethesda, Md), as previously described. E1 Results are expressed as the area of peribronchial a-smooth muscle actin staining per micrometer length of basement membrane of bronchioles 150 to 200 mm in internal diameter.
Lung inflammation: Eosinophils, CD4 hASM proliferation and contraction in vitro hASM cell counts were performed by means of either RT-qPCR detection of levels of Ki67 mRNA or quantitation of ASM cells by using light microscopy. hASM cells were used in an in vitro smooth muscle gel contraction assay previously described in our laboratory. E3 Briefly, transfected ASM cells were seeded in collagen gels free of LPS (Advanced BioMatrix, San Diego, Calif). After a 3-day incubation in collagen gels containing smooth muscle complete media (ScienCell, Carlsbad, Calif), hASM cells were cultured in the presence or absence of an agonist (50 mL of acetylcholine or histamine) or media control for 15, 30, and 60 minutes. With agonist-induced hASM contraction, the area of the gel decreases significantly. E3 The area of the gels was quantitated by using a Bio-Rad ImageDR transilluminator and Versadoc scanner (Bio-Rad Laboratories, Hercules, Calif) with an accompanying image capture and analysis program to generate area in square millimeters.
RT-qPCR
RT-qPCR was performed, as previously described, in this laboratory. E3 In brief, total RNA was extracted with RNA-STAT-60 (Tel-Test, Friendswood, Tex) and reverse transcribed with Oligo-dT and SuperScript II kit (Life Technologies, Grand Island, NY). RT-qPCR was performed with TaqMan PCR Master Mix and Ki67 or SERCA2b primers (all from Life Technology). Relative amounts of transcripts were normalized to those of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and compared between different genes by using the DD cycle threshold method, as previously described, in this laboratory.
E3
Preparation of PCLSs
Either WT or hORMDL3 zp3-Cre mice (5-to 7-week-old male mice) were killed by means of cervical dislocation at UCSD. After opening the thoracic cavity, the lungs were inflated with approximately 1 mL of air through an intratracheal catheter, tightened by a thread on the top end of the trachea, and shipped in Dulbecco modified Eagle medium (DMEM) supplemented with 20 mmol/L HEPES at 48C overnight to the University of Massachusetts Medical School. The lung was then warmed to approximately 378C, deflated by inserting an intratracheal catheter, and further inflated with approximately 1 mL of 1.8% agarose in sHBSS, followed by approximately 0.2 mL of air at approximately 378C. The agarose was then gelled with approximately 48C sHBSS. Lung lobes were removed and sectioned into approximately 180-mm-thick PCLSs by using a vibratome (VF-300; Precisionary Instruments, Greenville, NC), as previously described. E4 PCLSs were maintained in DMEM with antibiotics at either 378C or 258C and 10% CO 2 for up to 2 days. PCLS experiments were performed at 378C with constant perfusion by using a custom-made, temperature-controlled microscope enclosure, as previously described. E5 
Measurement of mouse airway contraction and relaxation
Briefly, mouse PCLSs were mounted on a perfusion chamber created by sandwiching the PCLSs between 2 cover glasses with the edges sealed by silicone grease. A 200-mm nylon mesh with a hole aligned over a selected airway was used to hold down the PCLSs. Phase-contrast images of airway lumen in response to different compounds was collected at a rate of 1 image per 2 seconds with a CCD camera mounted on an inverted microscope (Nikon Diaphot [Nikon, Tokyo, Japan] or Olympus IX71 [Olympus Center Valley, Pa]) with a 310 objective and controlled by custom-programed software based on Video Savant 4 (IO Industries, Montreal, Quebec, Canada), as previously described. E5 The change in lumen area of a selected airway was analyzed by using ImageJ software (National Institutes of Health, Bethesda, Md) and then normalized by using the following formula to quantify the airway contractility, as previously described E6 
:
Initial area ð%Þ 5 Lumen area at a certain time=Initial lumen area:
For the airway contraction assay, normalized contraction at a specific time point (5, 15, 25, 35 , and 45 minutes, respectively) when responding to a different concentration of agonist was used for dose-response curve drawing and statistical analysis.
To record CPA-induced airway relaxation (as a percentage), we initially normalized the contractile state of an airway (measured at the middle time point at 30 minutes in Fig 5, E) to its own initial contraction (measured at 15 minutes) by using the following formula:
RelaxationðR½%Þ 5 ðArea 30min 2Area 15min Þ=ð1002Area 15min Þ:
We then normalized the CPA-induced relaxation to the amount of relaxation that occurred in the control response by using the following formula:
These normalized relaxation responses to different concentrations of CPA were used for comparison and statistical analysis.
Measurement of [Ca 21 ] i signaling
Briefly, mouse PCLSs were incubated with sHBSS containing 20 mmol/L Oregon Green 488 BAPTA-1-AM, 0.1% Pluronic F-127, and 200 mmol/L sulfobromophthalein in the dark at approximately 308C for approximately 1 hour, followed by sHBSS containing 200 mmol/L sulfobromophthalein for an additional 30 minutes at room temperature to allow the de-esterification of Oregon Green. Mouse PCLS was mounted in the perfusion chamber, as described above. [Ca 21 ] i signaling, as reflected by the fluorescence change of Oregon Green in ASM cells of PCLSs, was monitored with a custom-built, video-rate, scanning 2-photon laser microscope E4,E7 at a rate of 15 images per second and controlled by using a custom-written image acquisition software based on Video Savant. The fluorescence intensity in a region of interest (ROI, 8 3 10 pixels) within an ASM cell with respect to time was determined by using custom-written software. Relative fluorescence intensity was expressed as F t /F 0 , a ratio of the fluorescence intensity at a particular time (F t ) normalized to the initial time (F 0 ). mASM cell culture mASM cells were obtained from WT and hORMDL3 zp3-Cre mice, as previously described. E1 In brief, after mouse death, tracheas were excised, cut longitudinally with a scalpel to expose the lumen, and then transferred to 0.14% Pronase (Roche Applied Science, Mannheim, Germany) in Ham F-12 nutrient medium and incubated at 48C overnight. Tracheas were then brushed with a cotton swab to remove the remaining adherent epithelial cells, cut into small pieces (approximately 30 per trachea), and cultured in DMEM/F-12 and 10% FBS for attachment and outgrowth. Four days later, mASM cell outgrowth was apparent, and the cells were left to multiply for 2 more days, after which they were trypsinized and plated into a 175-cm 2 flask. Confluency was reached within about 3 to 5 days. Experiments were done on the second passage, which was split 1:2 from the first passage.
hASM cell culture and transfection with SERCA2b siRNA Primary hASM cells were obtained from ScienCell. E3 hASM cells were maintained and cultured in flasks or plates (6-, 24-, and 96-well plates) by using smooth muscle cell medium with smooth muscle growth supplement (ScienCell) and 2% FBS. hASM cells were transfected with either control siRNA or SERCA2 siRNA (100 nmol/L) by using the transfection reagents siTran1.0 (OriGene, Rockville, Md) and Opti-MEM (Thermo Fisher Scientific, Pittsburgh, Pa), according to the manufacturer's instructions. The transfected hASM cells were used 48 hours after transfection in all experiments. We assessed the efficiency of SERCA2a and both SERCA2a and SERCA2b gene knockdown by using RT-qPCR, as previously described in this laboratory. E3 There are no primers specific for SERCA2b. In brief, total RNA was extracted with RNA-STAT-60 (Tel-Test) and reverse transcribed with Oligo-dT and SuperScript II kit (Life Technologies). RT-qPCR was performed with TaqMan PCR Master Mix and SERCA primers (all from Life Technology). Relative amounts of transcripts were normalized to those of the housekeeping gene GAPDH and compared between control siRNA-transfected samples and activating transcription factor 6a siRNA-transfected samples by using the DD cycle threshold method, as previously described in this laboratory. E3 
Chemicals and reagents
Oregon Green 488 BAPTA-1 AM was obtained from Life Technologies, ryanodine was obtained from Abcam (Cambridge, Mass), and other reagents were obtained from either Sigma-Aldrichor Thermo Fisher Scientific. sHBSS was adjusted to pH 7. A-D) were analyzed by using GraphPad Prism software (San Diego, Calif). All data are reported as means 6 SEMs. A P value of less than .05 was considered significant. A t test was used for analysis of 2 groups. ANOVA was used when more than 2 groups were compared.
University of Massachusetts. Results of experiments
performed at the University of Massachusetts (Figs 3, 4 , and 5, E-H, and see Figs E1-E3) were analyzed by using Origin 2016 software (OriginLab, Northampton, Mass). All data are reported as means 6 SEMs. A P value of less than .05 was considered significant. For multiple comparisons, 1-way (Fig 5, F and H (Fig E4, A) , followed by a summary of relaxation effect normalized to control values (Fig E4, B) . Control mice were treated with vehicle of 0.5% DMSO in sHBSS: P < .05. C, Representative trace shows 10 mmol/L CPA gradually stopped 400 nmol/L MCh-induced Ca 21 oscillations and lead to an increased Ca 21 baseline in an ASM cell of mouse PCLSs. Each line in Fig E4, A, represents the mean, and each point represents the mean 6 SEM at selected time points of the airway lumen area normalized to the initial size at a time of 0 seconds. Representative traces (Fig 4, C) are expressed as intensity (F t ) normalized to the initial intensity at a time of 0 seconds (F 0 ), as measured from a region of interest witha size of 8 3 10 pixels within a single ASM cell. Data in Fig E4, A and B , represent 8 to 10 airways for each line from 5 mice. Data in Fig E4, C, represent 7 ASM cells from 5 mice.
